Compare Cytokinetics Inc (CYTK) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Weibo Corp — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Weibo Corp trades at $6.51 (market cap $1.56B). The key difference: Cytokinetics Inc is far larger — about 5.5× Weibo Corp's market cap, and Weibo Corp pays a 9.47% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Weibo Corp for 102 Days on average.
| CYTK | WB | |
|---|---|---|
Market Cap | $8.62B | $1.56B |
Volume | 2,594,626 | 812,503 |
Sector | Health | Media |
52-Week High | $87.26 | $12.37 |
52-Week Low | $54.76 | $6.33 |
Typical Hold Time | 19 Days | 102 Days |
Enterprise Value | $8.72B | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Weibo (WB) trades at $6.48, down 0.15% with bearish technical signals. The stock shows attractive valuation metrics including a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent earnings show mixed performance with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing estimates. Cash flow trends indicate volatility with a significant net outflow in 2024 followed by recovery in 2025.
Weibo presents as a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising challenges. Analyst sentiment remains divided with 40.9% buy ratings versus 45.5% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition in social media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
